PR83718

SEOUL, South Korea, April 17, 2020 /PRNewswire=KYODO JBN/ --

Seegene, Inc., the leading multiplex diagnostic assay developer, today

announced that the company has exported over 10 million tests of Allple(TM)

2019-nCoV Assay to over 60 countries, which accounts for a significant portion

of globally performed COVID-19 test numbers.

Seegene's proactive decision to develop COVID-19 test kit with the capability

of rapid assay development using its proprietary AI-based big data system

allowed many countries to quickly expand the testing capacity, as the virus

started swamping all across the globe.

The demand for Seegene's assay continues to rise as it gained reputation for

its high quality and efficiency. The test has a unique feature that identifies

3 different target genes (E, RdRP and N genes) in a single reaction tube using

its own multiplex chemistry technologies, which allows for highly accurate

results and maximizes the throughput for high volume testing. Combined with its

automated system and advanced software, Seegene assay is globally proven to be

effective in high volume testing which is the key component in controlling

outbreak situations.

Seegene currently exports over 3 million tests a week. The company will reach

its manufacturing capacity over 20 million tests in May, and continue to scale

up its production to fulfill the unmet and increasing demand from all over the

world.

"We have been taking on new challenges every day to keep up with the global

need, as we continue to face unexpected issues in the process of explosive

increase in production and exports. I am extremely proud of what we have been

able to contribute to this fight against the virus and of the fact that our

cutting edge molecular diagnostic technologies have played a part in this

important fight" said Dr. Jong-Yoon Chun, CEO of Seegene.

Seegene also teamed up with its affiliate, Seegene Medical Foundation (SMF),

one of the reference laboratories in Korea with the largest capacity for

COVID-19 testing of up to 15,000 a day, to help countries in need for the virus

test exponentially and in emergency. SMF is ready to report the test result

within 24 hours upon the arrival of the samples from overseas. As the COVID-19

pandemic continues to wreak havoc all around the globe, Seegene and SMF have

been organized to do their part in providing the much needed tests and testing

capacity.

About Seegene

Seegene (KQ : 096530) is a global pioneer in symptom-based in vitro molecular

diagnostics focusing on advancing science to develop multiplex molecular

technologies and to manufacture multiplex in vitro diagnostic devices and

reagents. Seegene's core enabling power is the passion for wide spreading of

multiplex molecular diagnostics to improve the quality of life and health of

people. Using its innovative proprietary technologies, Seegene has been making

considerable contributions to giving the most economic and clinic-friendly

molecular diagnostic solutions for infectious diseases, genetics,

pharmacogenetics, and oncology. For more information, please visit

www.seegene.com.

SOURCE: Seegene